A Phase II Study of CRT Combined With QL1706 in ESCC Patients
This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
DRUG: QL1706
PFS assessed by investigators, Progression-free survival assessed by investigators, Up to approximately 2 years.
OS, Overall survival, 1year and 3years|ORR, Objective Response Rate，Complete Response plus Partial Response, Up to approximately 2 years|DoR, Duration of Response, Up to approximately 2 years|The rates and severity of Adverse Events, Serious Adverse Events, The rates and severity of Adverse Events, Serious Adverse Events, Through study completion, up to approximately 2 years
This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.